Clinical trials: Non-responders
Acute Ischemic Stroke
Non-responders to Antiplatelet Treatment in Acute Ischaemic Stroke)
Determination of frequency of Clopidigrel- and Acetacylicacid-non-responders (HOTPR) in acute ischemic stroke patients.
- Trial name
- NATIS (NCT02607358)
- Testing
- blood sampling for HOTPR-testing
- Where
- Denmark
- Volunteers
- 496 people
- Sponsor
- Zealand University Hospital
HIV-infection/Aids
Probiotic Supplementation for Those Immune Non-responders With HIV-1 Infection
Gut bacterial community diversity and composition, immune recovery and activation in peripheral plasma/mucosa, plasma levels of gut damage, microbial translocation and inflammation at baseline and after 6 months of receiving…
- Trial name
- NCT04297488
- Testing
- Bifidobacteria and Lactobacilli triple viable capsules
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking Union Medical College Hospital
HIV
Impact on T Cell Immune Activation and Inflammation of Triptolide Woldifii in HIV-infected Immunological Non-responders
This study is a prospective, multicenter, randomized, placebo-controlled clinical trial, to evaluate impact of Triptolide wilfordii on T cell immune activation and inflammation biomarkers in HIV-infected immunological…
- Trial name
- CACTrip12 (NCT01817283)
- Testing
- Triptolide, cART
- Where
- China
- Volunteers
- 150 people
- Sponsor
- LI Taisheng
Osteoporosis
The Effectiveness of Eldecalcitol in the Bisphosphonate Non-respondered-patients With Osteoporosis
In the patients with osteoporosis, bisphosphonates (BPs) are a golden standard treatment. However, the bone turnover markers or the bone mineral density (BMD) are not improved in some osteoporotic patients even though they have…
- Trial name
- NCT02306187
- Testing
- Edirol
- Where
- Japan
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Shinshu University
Obsessive-Compulsive Disorder
Mindfulness-Based Cognitive Therapy: Efficacy and fMRI-based Response Predictors in a Group of OCD Patients
Obsessive-Compulsive Disorder (OCD) patients have a response rate of 50-60% to exposure and response prevention (ERP) therapy and SSRI antidepressants.
- Trial name
- NCT03128749
- Testing
- Mindfulness Based Intervention, Treatment as Usual
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- Corporacion Parc Tauli
Rectal Cancer
Magnetic Resonance Tumour Regression Grade (mrTRG) as a Novel Biomarker - Phase III Non CTIMP Trial
Open to patients undergoing any pre-operative treatment for locally advanced rectal cancer, TRIGGER is the only phase III clinical trial in the UK offering watch and wait.
- Trial name
- TRIGGER (NCT02704520)
- Testing
- High resolution MRI scan, mrTRG assessment
- Where
- 10 sites in United Kingdom
- Volunteers
- 441 people
- Sponsor
- Imperial College London
Hepatitis C, HIV Infections
Peginterferon Alfa-2a, Ribavirin and Epoetin β in Coinfected Patients HCV/HIV Not Responding to Previous Treatment Regimens
This trial will assess the sustained virologic response to treatment with peginterferon alfa-2a combined with high-dose ribavirin in human immunodeficiency virus (HIV)-infected patients with hepatitis C virus (HCV) genotype 1 or…
- Trial name
- NCT00470210
- Testing
- Peginterferón alfa-2a (40 KD) (Pegasys®) 180 ug/week, Ribavirin (Copegus®) 1600 mg/day, Epoetin β (450 UI/kg/week)
- Where
- 2 sites in Spain
- Volunteers
- 10 people
- Sponsor
- Germans Trias i Pujol Hospital
Hepatitis C
A Study to Evaluate the Efficacy and Safety of Boceprevir Added to Standard of Care Therapy in Previously Treated Participants With Chronic Hepatitis C Genotype 1 and Cirrhosis (MK-3034-105)
This study is being done to find out if the addition of boceprevir to standard of care (SOC) treatment with peginterferon alfa-2b (PegIFN-2b) + ribavirin (RBV) is effective for participants with chronic hepatitis C (CHC) genotype…
- Trial name
- NCT01756079
- Testing
- boceprevir, PegIFN-2b, RBV
- Volunteers
- 58 people
- Sponsor
- Merck Sharp & Dohme LLC
Bowel Cancer Screening
Using Patient Navigation to Promote Bowel Screening in AAA Attendees.
The goal of this single-arm, multi-centre feasibility study is to assess the efficacy, feasibility and acceptability of implementing patient navigation across Abdominal Aortic Aneurysm (AAA) screening services in England to…
- Trial name
- TET BETA (NCT07721740)
- Testing
- Patient Navigation conversation
- Where
- United Kingdom
- Volunteers
- 4,190 people, healthy volunteers welcome
- Sponsor
- University of Surrey
Binge-Eating Disorder, Obesity
Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Medication Change for Non-Responders
This study will test the relative efficacy and effectiveness of the combination of naltrexone and bupropion (NB) medication as a treatment for binge-eating disorder (BED) in patients with obesity.
- Trial name
- NCT03946111
- Testing
- Naltrexone and Bupropion
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Yale University
GERD - PPI Responders, GERD - PPI Non-responders
Acid Pocket: Position and Aspiration
Gastroesophageal reflux disease (GERD) is a very common condition affecting up to 30% of adults. To date, therapy consists of powerful acid suppression with proton pump inhibitors (PPI).
- Conditions
- GERD - PPI Responders, GERD - PPI Non-responders, Barrett Esophagus, Healthy Volunteers
- Trial name
- NCT02199002
- Testing
- multi-pH-impedance manometry catheter
- Where
- Belgium
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- KU Leuven
Hepatitis B
Study to Evaluate Induction of HBV Virus Neutralizing Antibodies Using VVX001
The Study will evaluate the effects of VVX001, a novel vaccine for hepatitis B, to elicit a robust protective IgG immune response in vaccine naive subjects in subjects who failed to demonstrate seroconversion after treatment with…
- Trial name
- NCT03625934
- Testing
- VVX001
- Where
- 2 sites in Austria
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Viravaxx AG
Rheumatoid Arthritis
An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor
This multicenter, prospective, observational study will assess the efficacy of MabThera/Rituxan (rituximab) and alternative TNF-inhibitors in patients with rheumatoid arthritis who are non-responders or intolerant to a single…
- Trial name
- NCT01557348
- Where
- 215 sites in Canada, Colombia and 10 more
- Volunteers
- 1,239 people
- Sponsor
- Hoffmann-La Roche
HIV Infections
Maraviroc Immune Recovery Study
Rationale: Improving cellular immunity by means of increasing CD4 cells is one of the goals of antiretroviral therapy in HIV, which is achieved by means of virological suppression.
- Trial name
- MIRS (NCT00875368)
- Testing
- maraviroc
- Where
- 10 sites in Netherlands
- Volunteers
- 85 people
- Sponsor
- S.F.L. van Lelyveld
Diabetes Mellitus, Type 2
RF Vapor Ablation Retreatment of Duodenal Mucosa in Non-responders With Type-2 Diabetes Mellitus
The purpose of this study is to test the hypothesis that re-treatment of the duodenal mucosa with RF vapor ablation will result in improvement in glycemic parameters, without complications (bleeding/ stricture / perforation)…
- Trial name
- NCT06724822
- Testing
- RF Vapor Ablation
- Where
- Chile
- Volunteers
- 12 people
- Sponsor
- Aqua Medical, Inc.
Gastro Esophageal Reflux
Effectiveness of Physiologic Testing in PPI Non-Responders
The prevalence of GERD is estimated to be as high as 20% in the US, and up to 50% remain symptomatic on proton pump inhibitor (PPI) therapy.
- Trial name
- NCT03202537
- Testing
- dexlansoprazole
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- Northwestern University
Age-Related Macular Degeneration, Choroidal Neovascularization
Intravitreal Adalimumab in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
Adalimumab is a humanized recombinant monoclonal antibody fragment targeted against tumor necrosis factor. This study will assess the safety and efficacy of intravitreal adalimumab administered in patients with choroidal…
- Trial name
- NCT01136252
- Testing
- Adalimumab
- Where
- Spain
- Volunteers
- 5 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Macular Degeneration
Genetics in Non-response to Anti-VEGF Treatment in Exudative AMD
To assess genetic features and intraocular cytokine profiles of non-responders to anti-VEGF treatment of exudative age-related macular degeneration. Also to assess necessity and frequency of pro re nate medical re-treatment.
- Trial name
- RESPONSE (NCT01213667)
- Testing
- Ranibizumab
- Where
- Germany
- Volunteers
- 110 people
- Sponsor
- University of Cologne
Hepatitis C
Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous Treatment
The study is to investigate whether participants with hepatitis C virus (HCV) genotype 1 who have a history of non-response/relapse to peginterferon alfa-2a (PEG) and ribavirin (RBV) may benefit from treatment with triple therapy…
- Trial name
- NCT01183169
- Testing
- Alisporivir, Peginterferon alfa-2a, Ribavirin
- Where
- 75 sites in United States, Australia and 12 more
- Volunteers
- 459 people
- Sponsor
- Debiopharm International SA
Irritable Bowel Syndrome With Diarrhea
Changes in Microbiota and Metabolomic Profile Between Rifaximin Responders and Non-responders In Diarrhoea-Predominant Irritable Bowel Syndrome
Irritable Bowel Syndrome (IBS) carries a high prevalence worldwide and imposes substantial economic burden on patients, healthcare systems and society.
- Trial name
- NCT03557788
- Testing
- Rifaximin Oral Tablet
- Where
- Singapore
- Volunteers
- 33 people
- Sponsor
- National University Hospital, Singapore